$20.53
+1.2%Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as amyotrophic lateral sclerosis and duchenne muscular dystrophy; infusion therapies for bleeding disorders; therapies that women need to survive and thrive through high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. Option Care Health, Inc. is headquartered in Bannockburn, Illinois.
Last Annual Value
682.45M
3-Year CAGR
3%
5-Year CAGR
4%
10-Year CAGR
2%
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
![]() Option Care Health, Inc. NASDAQ:OPCH | 682.45M | 0.8% | 3.0% | 8.6% | |
![]() Akero Therapeutics, Inc. NASDAQ:AKRO | 285.42M | 18.2% | 23.1% | N/A | |
![]() ADMA Biologics, Inc. NASDAQ:ADMA | 101.32M | 14.6% | 11.2% | 16.7% | |
![]() Oscar Health, Inc. NYSE:OSCR | 2.08B | 12.6% | -3.6% | N/A | |
![]() Hinge Health, Inc. NYSE:HNGE | 1.01B | 46.2% | N/A | N/A | |
![]() ACADIA Pharmaceuticals Inc. NASDAQ:ACAD | 877.70M | 5.2% | 6.7% | 11.9% | |
![]() Immunovant, Inc. NASDAQ:IMVT | 532.90M | 36.8% | 37.6% | N/A | |
![]() Lantheus Holdings, Inc. NASDAQ:LNTH | 631.12M | 22.3% | 20.5% | 21.8% | |
![]() Indivior Pharmaceuticals Inc NASDAQ:INDV | 728.00M | -12.2% | 10.1% | 3.4% | |
![]() TransMedics Group, Inc. NASDAQ:TMDX | 254.22M | 11.6% | 33.2% | 26.8% | |
![]() Kymera Therapeutics, Inc. NASDAQ:KYMR | 388.60M | 16.8% | 17.5% | N/A |
Continue your OPCH research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.